OT mobile menu



Immune Checkpoint Inhibitors Causing Rheumatic Events

Opdivo and Yervoy may cause inflammatory arthritis and sicca syndrome among some patients. Image © blackboard1965/Shutterstock.com 

Recent Content

Juno Therapeutics has reopened the phase II clinical trial (ROCKET trial) of JCAR015 in adult patients with B-cell acute lymphoblastic leukemia following three deaths.

Prescribing nivolumab only to patients with programmed cell death ligand 1-positive (PD-L1+) tumors improves its cost-effectiveness.

Virginia Cancer Specialists reported they have enrolled the first patient in a new advanced lung cancer clinical trial for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.

Circulating tumor DNA detected after resection of stage II colon cancer appears to identify patients who are at high-risk of tumor recurrence.

Adding neratinib to standard paclitaxel chemotherapy appears to be associated with a better pathological complete response rate than chemotherapy plus trastuzumab.

Researchers from the University of Michigan have developed new technology to separate aggressive stage 0 breast cancer from nonaggressive forms.

Researchers are reporting they have identified ERCC3 as a new target for pancreatic cancer and demonstrated the effects are extremely strong in a molecularly defined subset of patients.

By clicking Accept, you agree to become a member of the UBM Medica Community.